CagrisSema is a once weekly injection of semaglutide and cagrilintide. Phase 2 clinical trial results for CagriSema showed significant improvements in A1C, weight loss, and time in range, marking it as a promising Clinical impact of semaglutide on obesity management CPAA Dove Medical Press VisualAbstract: Cagrilintide Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes 2 Minute Medicine Good looking results for Novo Nordisk's combo of GLP1ra semaglutide (known as #ozempic for #diabetes & #wegovy for obesity) + Cagrilintide (amylin agonist) to achieve #weightloss in obesity and obesity with type Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 24 mg for weight management: a randomised, controlled, phase 1b trial The Lancet Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema in Adults with Overweight or Obesity: A Bayesian Network Meta Analysis Journal of Clinical Question